126 related articles for article (PubMed ID: 36093649)
1. CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients.
Manganaro L; Celli V; Viggiani V; Berardelli E; Granato T; Tartaglione S; Farina A; Catalano C; Angeloni A; Anastasi E
Tumour Biol; 2022; 44(1):171-185. PubMed ID: 36093649
[TBL] [Abstract][Full Text] [Related]
2. Elevated Serum Level of CA125 Is a Biomarker That Can Be Used to Alter Prognosis Determined by BRCA Mutation and Family History in Ovarian Cancer.
Liu W; Wang Z; Ma J; Hou Y; Zhao J; Dong B; Tu S; Wang L; Guo Y
Genet Test Mol Biomarkers; 2017 Sep; 21(9):547-554. PubMed ID: 28799806
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
[No Abstract] [Full Text] [Related]
4. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
5. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
6. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
7. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.
Stiekema A; Lok CA; Kenter GG; van Driel WJ; Vincent AD; Korse CM
Gynecol Oncol; 2014 Mar; 132(3):573-7. PubMed ID: 24418200
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [
Glickman A; Paredes P; Carreras-Diéguez N; Niñerola-Baizán A; Gaba L; Pahisa J; Fusté P; Del Pino M; Díaz-Feijóo B; González-Bosquet E; Agustí N; Sánchez-Izquierdo N; Fuster D; Perissinotti A; Romero I; Fernández-Galán E; Carrasco JL; Gil-Ibáñez B; Torné A
Eur Radiol; 2022 Apr; 32(4):2200-2208. PubMed ID: 34586465
[TBL] [Abstract][Full Text] [Related]
9. The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients.
Ikeda Y; Hasegawa K; Kurosaki A; Miyara A; Hanaoka T; Shintani D; Imai Y; Nishikawa T; Oda K; Fujiwara K
Oncol Res Treat; 2015; 38(6):276-81. PubMed ID: 26045023
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
12. CA125 Levels in BRCA mutation carriers - a retrospective single center cohort study.
Gebhart P; Singer CF; Gschwantler-Kaulich D
BMC Cancer; 2023 Jul; 23(1):610. PubMed ID: 37393265
[TBL] [Abstract][Full Text] [Related]
13. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
[TBL] [Abstract][Full Text] [Related]
15. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation.
Lee YJ; Kim W; Hong S; Lee YJ; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38670560
[TBL] [Abstract][Full Text] [Related]
17. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
18. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of CA125, HE4, and systemic immune-inflammation index in the preoperative investigation of ovarian masses.
Song L; Qi J; Zhao J; Bai S; Wu Q; Xu R
Medicine (Baltimore); 2023 Sep; 102(37):e35240. PubMed ID: 37713838
[TBL] [Abstract][Full Text] [Related]
20. Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
Lentz SE; Powell CB; Haque R; Armstrong MA; Anderson M; Liu Y; Jiang W; Chillemi G; Shaw S; Alvarado MM; Kushi LH; Skates SJ
Gynecol Oncol; 2020 Dec; 159(3):804-810. PubMed ID: 33012551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
